Start free

PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Excellus BlueCross BlueShieldCommercial · Coverage · Genetic Disease (Inherited Disease) · NY · Genetics, PediatricsMedium impact

Whole Exome and Whole Genome Sequencing for Diagnosis of Genetic Disorders 2.02.46

Effective date
Sep 17, 2026
Identified
Jun 20, 2026

Summary

Policy 2.02.46 considers whole exome sequencing, with trio testing when possible, medically appropriate for an unexplained congenital or neurodevelopmental disorder only when all criteria are met: a genetic cause is the most likely explanation despite previous genetic testing, the clinical presentation does not fit a single well-described syndrome or an invasive next step is needed, a clinician with expertise in clinical genetics has evaluated the patient and counseling about the risks of genetic testing is documented, the diagnosis cannot be established by standard clinical work-up, and there is potential for a change in management and clinical outcome. Whole mitochondrial genome sequencing may be considered when signs and symptoms of a mitochondrial disorder are present and genetic testing may eliminate the need for muscle biopsy. Whole genome sequencing, prenatal and preimplantation exome or genome sequencing, repeat exome or genome sequencing, and the EpiSign epigenetic assay are listed as investigational for the diagnosis of genetic disorders.

Get alerts when payers change rules like this one

We check Excellus BlueCross BlueShield and other payers every day and email you when a change matches your specialty and state.

Get Excellus BlueCross BlueShield alertsPolicy Monitoring is free. No card required.

What to do

Action · 9 steps
01Current version effective September 17, 2026: Before billing whole exome sequencing for an unexplained congenital or neurodevelopmental disorder, confirm the record documents at least two of the six listed findings, such as an abnormality affecting at least one organ system, significant developmental or intellectual delay, a family history strongly suggesting a genetic etiology, unexplained developmental regression, inability to explain symptoms by other causes, or biochemical findings suggestive of an inborn error of metabolism.
02Confirm the record documents either a clinical presentation that does not fit a single well-described syndrome or an invasive next diagnostic step such as muscle biopsy.
03Confirm the record includes an evaluation by a clinician with expertise in clinical genetics, with family history, a phenotype description, and counseling about the risks of genetic testing, and that standard clinical work-up cannot establish or confirm the diagnosis.
04Where no previous genetic testing was completed, document a valid justification for why chromosomal microarray and/or targeted gene testing is not appropriate for the member.
05Where family history or phenotype suggests a specific syndrome, document targeted testing for the associated mutation before more extensive testing, or document the rationale for more extensive testing.
06Document how the test results will affect treatment or medical management, since testing should be performed for management or treatment and not only for knowledge purposes.
07Confirm the performing laboratory is certified under CLIA.
08Trio testing of the child and both parents is the recommended option when possible.
09Confirm the member has a valid contract, because coverage is not provided for family members without a valid contract.

Codes mentioned

81401814038140481405814068140781408814158141681417814258142681427814408146081465

Original notice

Whole Exome and Whole Genome Sequencing for Diagnosis of Genetic Disorders 2.02.46
excellusbcbs.com · Always check the source before changing claims.
View original ↗

Related changes

See all Excellus BlueCross BlueShield changes →
Genetic Testing for Thoracic Aortic Aneurysms/ Dissections and Connective Tissue Related Disorders 2.02.61MediumEffective Sep 17, 2026 · Genetic Disease (Inherited Disease)Genetic Testing for Thoracic Aortic Aneurysms/ Dissections and Connective Tissue Related Disorders 2.02.61MediumEffective Sep 17, 2026 · Genetic Disease (Inherited Disease)Genetic Testing for Inherited Disorders 2.02.03MediumEffective Dec 18, 2025 · Genetic Disease (Inherited Disease)Germline Genetic Testing for Hereditary Cancers 2.02.60MediumEffective Apr 16, 2026 · Genetic Disease (Inherited Disease)Browse every Excellus BlueCross BlueShield change in the policy list

Related policy hubs

Excellus BlueCross BlueShield policiesNY policy changesGeneticsPediatricsCode 81401Code 81403Code 81404Code 81405Code 81406Code 81407Code 81408Code 81415Code 81416Code 81417Code 81425Code 81426Code 81427Code 81440Code 81460Code 81465

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Policy MonitoringPayer policy, prior auth and coding changes, filtered to your saved searchesOIG ScreeningStaff and vendors screened every month against OIG LEIE, SAM.gov and state Medicaid listsPrior Auth LookupKnow if a service needs prior authorization before you schedule itCredentialing TrackerLicenses, CAQH, Medicare revalidation and payer enrollments, with reminders before anything lapsesCompliance CenterKeep your HIPAA program documented and ready to show
Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account